The firm's mission is to create new knowledge driven by data, computation, automation and high-throughput robotics with the goal of fundamentally advancing life science. Strateos aims to help scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/10/21 | $56,100,000 | Series B |
Ally Bridge Group Black Diamond Ventures Castor Ventures DCVC  Eli Lilly and Company Lux Capital Mack Capital | undisclosed |
